COX-2 in Neurological Disorders Related to MS: Insights from a Systematic Review
A systematic review indicates that COX-2 is crucial in promoting neuroinflammation and advancing multiple sclerosis (MS). It suggests that selective COX-2 inhibitors could provide neuroprotective effects, particularly in early stages of the disease or when combined with other therapies.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
Understanding COX-2's role in MS can guide future therapeutic strategies, but inconsistent clinical trial results and cardiovascular risks associated with COX-2 inhibitors highlight the need for caution.
What this does not prove
The review notes the challenges in translating laboratory findings to clinical practice due to the complex nature of COX-2's functions and the varying results of clinical trials.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-18
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceIntegrative Perspectives on COX-2 Signaling and Selective Inhibitors in Central Nervous System Disorders: A Narrative Review. ↗DOI: 10.2174/0109298673496586260831110156
Supporting passages (5)
study designMETHODS: For this review, we gathered and carefully analyzed published literature related to COX-2 signaling in CNS disorders.
publication datePublication date: 2026-09-18
interventionSelective COX-2 inhibitors show promising neuroprotective potential, especially in early stages or in combination therapies, but inconsistent efficacy and cardiovascular risks necessitate safer next- generation inhibitors.
findingsCONCLUSION: COX-2 plays a central role in driving neuroinflammation and disease progression in AD, PD, ALS, schizophrenia, MS, MDD, and epilepsy.
limitationsHowever, failures in some clinical trials highlight the complexity of translating preclinical findings into patient care.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.